Clinical efficacy of famitinib malate for treatment of metastatic renal cell carcinoma—a report of 9 cases
10.3724/SP.J.1008.2015.01348
- Author:
Bing LIU
1
Author Information
1. Department of Urology, Changzheng Hospital, Second Military Medical University
- Publication Type:Journal Article
- Keywords:
Famitinib;
Neoplasm metastasis;
Outcome;
Renal cell carcinoma;
Target therapy
- From:
Academic Journal of Second Military Medical University
2015;36(12):1348-1351
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the clinical effect of famitinib malate for treatment of metastatic renal cell carcinoma (mRCC%. Methods Nine mRCC patients treated with famitinib malate in our center completed their follow-up from October 2011 to June 2015. The patients received famitinib malate at an initial dose of 25 mg, which was given orally before breakfast once a day. One cycle consisted of 42 days. The antitumor efficacy and the adverse event (AE% were observed. Results After treatment with famitinib for 3 cycles, the objective response rate (ORR% reached 66. 7 Y (6/9% for the patients, with partial remission (PR% found in 6 patients, stable disease (SD% in 2 patients and progressive disease (PD% in 1. The median follow-up time was 29 months (15-40 months% in our study and the median progression free survival (PFS% was 16. 5 months (4. 5-38. 0 months%. The most common treatment-related AE of famitinib malate was proteinura, and other AEs were similar to those of sunitinib. Six patients had reduction and interruption as appropriate due to AEs, and 2 patients stopped the treatment due to intolerable proteinuria. Conclusion Famitinib malate has a good antitumor activity upon mRCC, and its adverse reaction is controllable, making it a promising molecule-targeted drug for clinical application.
